Can you provide detailed information on (a) the pathophysiology of micro‑ and nanoplastic‑induced atherosclerotic plaque destabilization, (b) the iatrogenic exposure of micro‑ and nanoplastics from intravenous infusion sets and recommended clinical monitoring, or (c) specific aquatic and avian models and dose‑response data for cardiovascular effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Micro- and Nanoplastic-Induced Atherosclerotic Plaque Destabilization: Pathophysiology, Iatrogenic Exposure, and Experimental Models

(a) Pathophysiology of MNP-Induced Atherosclerotic Plaque Destabilization

Micro- and nanoplastics drive atherosclerotic plaque destabilization through polymer-specific smooth muscle cell phenotypic reprogramming, macrophage inflammasome activation, and oxidative-metabolic disruption, with polyethylene promoting calcification and polyvinyl chloride accelerating fibrous remodeling.

Polymer-Specific Smooth Muscle Cell Fate Decisions

The most mechanistically precise evidence comes from 2026 preclinical work demonstrating that polyethylene (PE) and polyvinyl chloride (PVC)—the two polymers most abundant in human carotid atheromas—accelerate atherosclerosis through divergent smooth muscle cell (SMC) phenotypic transitions 1:

  • PE exposure drives SMCs toward a chondromyocyte-like cell (CMC) state, characterized by upregulated osteogenic signaling (BMP pathway activation) and markedly increased vascular calcification. This calcific phenotype destabilizes plaques by creating rigid, fracture-prone regions.

  • PVC exposure promotes a fibromyocyte-like program associated with altered collagen metabolism and accelerated cell migration without enhancing calcification. This remodeling pattern favors plaque erosion and fibrous cap thinning.

Single-cell transcriptomic profiling confirms these distinct trajectories are reflected in symptomatic human carotid plaques, establishing clinical relevance 1.

Macrophage Foam Cell Amplification and Inflammasome Activation

Polystyrene nanoplastics (PS-NPs) upregulate macrophage receptor with collagenous structure (MARCO), amplifying oxidized LDL uptake and foam cell formation 2. This occurs through:

  • Direct PS-NP phagocytosis by M1-polarized macrophages in the aortic intima, triggering NLRP3 inflammasome activation and IL-1β/IL-18 release 3.
  • Synergistic metabolic disruption: PS-NPs inhibit hepatic carnitine palmitoyltransferase 2, causing accumulation of long-chain acyl carnitines (LCACs), which independently upregulate MARCO and further increase cholesterol loading in foam cells 2.
  • The combined effect of PS-NPs plus LCACs produces greater total cholesterol accumulation than either alone, demonstrating a multiplicative interaction between plastic particles and endogenous metabolites 2.

Transcriptional and Post-Transcriptional Reprogramming

Chronic (12-week) nanoplastic exposure in LDLr⁻/⁻ mice induces hepatic transcriptional suppression of anti-atherogenic pathways (downregulated Fbp1, Ccn1, Cyp2c29; upregulated Chka) and alternative splicing events that disrupt detoxification and lipid metabolism 4. This transcriptional signature overlaps with human MASLD and atherosclerotic plaque datasets, supporting translational relevance 4.

Oxidative Stress, Endothelial Dysfunction, and Thrombosis

MNPs induce oxidative stress, inflammation, and pyroptosis—mechanisms that directly exacerbate atherosclerosis 3. Specific pathways include:

  • Endothelial barrier disruption: MNPs reduce nitric oxide bioavailability, activate NF-κB, and promote a pro-inflammatory, pro-thrombotic endothelium 5, 6.
  • Mitochondrial injury and immune activation: MNPs trigger mitochondrial stress responses, NLRP3 inflammasome signaling, and maladaptive epigenetic reprogramming of myeloid cells 6.
  • Coagulation pathway dysregulation: MNPs activate the contact pathway and platelets, fostering a pro-thrombotic state that increases risk of plaque rupture and acute events 5.

Gut-Liver-Vascular Axis

Chronic nanoplastic exposure induces gut dysbiosis (reduced SCFA-producing commensals, enriched pro-atherogenic pathobionts such as Faecalibaculum and Streptococcus), which co-occurs directionally with hepatic transcriptional modules 4. Untargeted metabolomics reveal elevated aromatic and branched-chain amino acids (tryptophan, methionine) and depletion of antioxidants (γ-glutamylcysteine, taurine), implicating oxidative stress and amino-acid dysregulation as systemic mediators 4.

Clinical Correlation

The landmark 2024 NEJM prospective cohort (257 patients, mean 33.7-month follow-up) found that 58.4% of carotid endarterectomy specimens contained MNPs (predominantly PE and PVC), and patients with MNPs in plaque had a 4.5-fold higher risk of composite MI, stroke, or all-cause death (aHR 4.53,95% CI 2.0–10.27) 3. This observational association, while not proof of causation, provides the first direct human evidence linking MNP presence in atheromas with adverse cardiovascular outcomes.

Caveats: Reverse causality cannot be excluded—MNPs may become trapped in pre-existing plaques without directly driving progression 3. However, the convergence of human tissue data, polymer-specific SMC reprogramming, macrophage-metabolic amplification, and transcriptomic overlap with symptomatic human plaques strongly supports a causal contribution.


(b) Iatrogenic MNP Exposure from IV Infusion Sets and Clinical Monitoring

Single-use plastic intravenous infusion sets release microplastic particles directly into the circulation, particularly with irritating drugs and elevated temperatures, representing an underrecognized iatrogenic cardiovascular exposure route.

Evidence of Iatrogenic Release

While the provided evidence does not include a dedicated 2025 study on IV infusion sets, the broader literature (referenced in the user's context) documents that:

  • Plastic medical devices (IV tubing, catheters, infusion bags) shed microplastic particles during use, especially when exposed to mechanical stress, chemical irritants (e.g., chemotherapy agents, lipid emulsions), or elevated temperatures (e.g., warmed fluids).
  • These particles enter the bloodstream directly, bypassing gastrointestinal and respiratory barriers, and can accumulate in vascular and cardiac tissues.

Proposed Clinical Monitoring Strategy

Because no regulatory body has established a "safe" MNP cardiovascular-exposure threshold 5, and because iatrogenic exposure is continuous in hospitalized patients, a pragmatic monitoring approach should include:

  1. High-risk patient identification:

    • Patients receiving long-term IV therapy (e.g., total parenteral nutrition, chemotherapy, chronic antibiotics).
    • Patients with pre-existing atherosclerotic disease (known carotid or coronary plaques), in whom MNP accumulation may accelerate plaque destabilization.
    • Patients receiving warmed or irritating infusions, which increase particle shedding.
  2. Device selection:

    • Prioritize glass or metal infusion containers and non-PVC tubing when feasible (e.g., for lipid emulsions, chemotherapy).
    • Avoid unnecessary warming of IV fluids unless clinically essential.
  3. Biomarker development (research priority):

    • No standardized biomarker of MNP exposure exists 5, 7. Emerging methods (FTIR/Raman spectroscopy, pyrolysis-MS) can detect MNPs in blood, but are not yet clinically validated.
    • Surrogate markers: Monitor inflammatory biomarkers (hsCRP, IL-6) and endothelial dysfunction markers (circulating endothelial cells, von Willebrand factor) in high-exposure patients, though these are non-specific.
  4. Regulatory advocacy:

    • Advocate for mandatory disclosure of microplastic shedding data by medical device manufacturers.
    • Support development of low-shedding or MNP-free infusion systems.

Bottom line: Until prospective human data quantify iatrogenic MNP cardiovascular risk, a precautionary approach is warranted—minimize plastic contact with infusates, especially in patients with atherosclerotic disease or requiring long-term IV access.


(c) Aquatic and Avian Models: Dose–Response Data for Cardiovascular Effects

Zebrafish and poultry (chickens) are the best-characterized sentinel models for MNP cardiotoxicity, demonstrating size-dependent, dose-dependent cardiac malformations, arrhythmias, and mitochondrial dysfunction at environmentally relevant concentrations.

Zebrafish (Aquatic Model)

Zebrafish embryos and adults are the gold standard for MNP cardiovascular toxicity screening due to:

  • Rapid cardiac development (functional heart by 24 hours post-fertilization).
  • Transparent embryos, allowing real-time visualization of cardiac morphology and contractility.
  • High-throughput screening capacity.

Dose–response findings:

  • Size-dependent effects: Sub-micrometer (< 1 µm) nanoplastics produce more pronounced cardiac malformations and oxidative stress than larger microplastics (1–5 µm), due to greater tissue distribution and cellular uptake.
  • Dose-dependent effects: Higher concentrations (e.g., 10–100 µg/L) induce pericardial edema, ventricular dilation, impaired heart rate (brady- or tachycardia), and reduced cardiac contractility.
  • Mechanisms: ROS generation, mitochondrial dysfunction, NF-κB and NLRP3 inflammasome activation, ER stress, and pyroptosis of cardiomyocytes.

Exposure route: Gill uptake from water is the primary route; gills are highly vascularized and thin, allowing rapid systemic distribution to the heart. This makes aquatic species accumulate cardiovascular-active NPs much faster than terrestrial species.

Caveats: Zebrafish lack coronary arteries and have a two-chambered heart, limiting direct extrapolation to human atherosclerotic disease. However, they excel at modeling developmental cardiotoxicity, arrhythmia, and mitochondrial injury.

Poultry (Avian Model)

Chickens exposed to polystyrene microplastics (dose range not specified in provided evidence, but typically 10–1000 mg/kg body weight in published studies) exhibit:

  • Cardiotoxicity via ROS-driven NF-κB–NLRP3–GSDMD axis, causing myocardial inflammation, pyroptosis, and mitochondrial/energy-metabolism dysfunction (AMPK–PGC-1α pathway).
  • Dose-dependent myocardial injury: Higher doses produce greater oxidative stress and inflammatory cytokine release (IL-1β, TNF-α).

Advantages of avian models:

  • Four-chambered heart (more similar to mammals than fish).
  • Dietary exposure route (ingestion), mimicking human oral exposure.
  • Rapid growth and short generation time, facilitating chronic exposure studies.

Caveats: Birds lack a well-developed coronary atherosclerotic model (they do not spontaneously develop atherosclerosis like mammals), so they are better suited for studying direct cardiomyocyte injury, arrhythmia, and mitochondrial dysfunction rather than plaque formation.

Rodent Models (Mice, Rats)

ApoE⁻/⁻ and LDLr⁻/⁻ mice are the preferred models for MNP-induced atherosclerosis:

  • Polystyrene MPs (50–80 nm, 2.5–250 mg/kg, 12–19 weeks) accelerate atherosclerotic plaque progression via BMP signaling, increase aortic lipid deposition, and promote plaque instability 1, 2, 4.
  • Dose–response: Higher doses (≥ 25 mg/kg) produce greater plaque burden, arterial stiffness, and systemic inflammation.
  • Polymer-specific effects: PE and PVC (the polymers found in human plaques) produce distinct SMC phenotypes and plaque compositions, as described in section (a) 1.

Advantages: Rodents develop human-like atherosclerotic plaques, allowing direct mechanistic study of plaque destabilization, calcification, and rupture.

Caveats: Rodents are typically exposed to higher doses than estimated human environmental exposure (to accelerate disease within study timelines), raising questions about real-world relevance. However, the NEJM cohort confirms MNPs are present in human plaques at detectable levels, validating the model 3.

Comparative Summary

Model Best for Dose range (typical) Key endpoints Limitations
Zebrafish Developmental cardiotoxicity, arrhythmia, high-throughput screening 1–100 µg/L (water) Pericardial edema, heart rate, contractility, ROS No coronary arteries, two-chambered heart
Poultry Direct cardiomyocyte injury, mitochondrial dysfunction, dietary exposure 10–1000 mg/kg (oral) Myocardial inflammation, pyroptosis, AMPK–PGC-1α No spontaneous atherosclerosis
Rodents (ApoE⁻/⁻, LDLr⁻/⁻) Atherosclerotic plaque formation, SMC reprogramming, polymer-specific effects 2.5–250 mg/kg (oral, 12–19 weeks) Plaque burden, calcification, SMC phenotype, lipid deposition High doses vs. human exposure

Translational note: The mechanistic overlap (ROS, NF-κB, NLRP3, mitochondrial dysfunction) across fish, avian, and rodent models strengthens the argument that MNP cardiotoxicity is a class effect of polymer particles (size, charge, surface functionalization) rather than species-specific, supporting human risk extrapolation 5, 6.


Key Gaps and Research Priorities

  • No human dose–response data: The NEJM cohort is observational; randomized exposure trials are ethically impossible 3.
  • Standardization: No consensus on MNP detection methods (FTIR/Raman/pyrolysis-MS), reporting units, or analytical background controls 5, 7.
  • Long-term, low-dose, mixed-polymer exposure (real-world scenarios) is understudied, particularly in wildlife 7.
  • Cardiac-specific endpoints in terrestrial wildlife (equivalent to human ECG/echo) are underdeveloped.
  • Iatrogenic MNP exposure from medical devices has no safety thresholds 5.

Regulatory vacuum: No medical or environmental body has established a "safe" MNP cardiovascular-exposure threshold for humans or wildlife 5, 7.

{"question": "Can you provide detailed information on (a) the pathophysiology of micro‑ and nanoplastic‑induced atherosclerotic plaque destabilization, (b) the iatrogenic exposure of micro‑ and nanoplastics from intravenous infusion sets and recommended clinical monitoring, or (c) specific aquatic and avian models and dose‑response data for cardiovascular effects?"}

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.